Atovaquone
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Mepron |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693003 |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 2.2–3.2 days |
| Identifiers | |
| |
JSmol) | |
| Melting point | 216 to 219 °C (421 to 426 °F) |
SMILES
| |
| |
  (what is this?) (verify) | |
Atovaquone, sold under the brand name Mepron, is an antimicrobial medication for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP).[2]
Atovaquone is a chemical compound that belongs to the class of
Medical uses
Atovaquone is a medication used to treat or prevent:
- For pneumocystis pneumonia (PCP),[3][4] it is used in mild cases, although it is not approved for treatment of severe cases.
- For toxoplasmosis,[5] the medication has antiparasitic and therapeutic effects.
- For Malarone. Malarone has fewer side effects and is more expensive than mefloquine.[6] Resistance has been observed.[7]
- For babesia, it is often used in conjunction with oral azithromycin.[8]
Atovaquone is given prophylactically to kidney transplant patients to prevent PCP in cases where Bactrim is contraindicated for the patient.[medical citation needed]
Malaria
Atovaquone, as a
Research
COVID-19
 | This section needs to be updated. (November 2022) |
Preliminary research found that atovaquone could inhibit the replication of SARS-CoV-2 in vitro.[9] Clinical trials of atovaquone for the treatment of COVID-19 are planned,[10][11] and ongoing in United States in December 2021.[12][needs update]
Atovaquone has also been found to inhibit human coronavirus OC43 and feline coronavirus in vitro.[13]
In newer researches, atovaquone did not demonstrate evidence of enhanced SARS-CoV-2 viral clearance compared with placebo.[14]
Veterinary use
Atovaquone is used in livestock veterinary cases of babesiosis in cattle, especially if imidocarb resistance is a concern.[15]
References
- ^ "Wellvone 750mg/5ml oral suspension - Summary of Product Characteristics (SmPC)". (emc). 28 November 2019. Retrieved 18 September 2020.
- ^ "Atovaquone Oral SUSPENSION- atovaquone suspension". DailyMed. 10 December 2019. Retrieved 18 September 2020.
- PMID 8479489.
- S2CID 24263604.
- PMID 12461021.
- ^ Malarone: New Malaria Medication With Fewer Side-effects Archived May 14, 2006, at the Wayback Machine
- PMID 12649236.
- PMID 11078770.
- S2CID 219428383. Retrieved 20 June 2020.
- ^ "Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection". ClinicalTrials.gov. Retrieved 22 October 2020.
- ^ "Atovaquone for Treatment of COVID-19". ClinicalTrials.gov. Retrieved 22 October 2020.
- ^ KATHRINE EMILIE KRISTENSEN (10 December 2021). "Ny forskning finder lægemiddel mod corona: 'Kan redde menneskeliv'". B.T. (in Danish). Retrieved 10 December 2021.
- PMID 32563698.
- PMID 36249792.
- PMID 16504402.
Further reading
- Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL (January 2004). "Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae". The Journal of Biological Chemistry. 279 (4): 2817–2824. PMID 14576156.
External links
- "Atovaquone". Drug Information Portal. U.S. National Library of Medicine.